S3I-201, a STAT3 Inhibitor, Inhibits Proinflammatory Mediator Signalling in CD19 and CD45R/B220 Cells in a Mouse...

Area of Science:

• Neuroimmunology
• Pharmacology
• Cellular Biology

Background:

• Multiple Sclerosis (MS) is a chronic central nervous system (CNS) disease with limited treatment options and significant side effects.
• Signal Transducer and Activator of Transcription 3 (STAT3) inhibitors are being explored for immunological diseases.
• S3I-201 is a known STAT3 inhibitor with potential therapeutic applications.

Purpose of the Study:

• To evaluate the efficacy of S3I-201 in treating experimental autoimmune encephalomyelitis (EAE), an animal model for MS.
• To investigate the impact of S3I-201 on inflammatory markers within B cells and brain tissue in EAE mice.

Main Methods:

• EAE was induced in SJL/J mice using PLP139-151.
• S3I-201 (10 mg/kg) was administered daily from day 14 to day 35 post-induction.
• Flow cytometry and RT-PCR were used to assess the expression of IL-6, iNOS, Notch1, Notch3, GM-CSF, and NF-κB p65 in B cells and brain tissue.

Main Results:

• S3I-201 treatment significantly reduced the number of B cells expressing IL-6, iNOS, Notch1, Notch3, GM-CSF, and NF-κB p65.
• S3I-201 administration led to decreased mRNA expression of these inflammatory mediators in the brain tissue of EAE mice.
• S3I-201 demonstrated inhibition of inflammatory mediator signaling through various cellular pathways.

Conclusions:

• S3I-201 effectively ameliorates EAE in mice, suggesting a potential therapeutic role in multiple sclerosis.
• The drug's mechanism involves inhibiting key inflammatory signaling pathways, including those involving IL-6, iNOS, Notch, and NF-κB.
• S3I-201 may offer a novel treatment strategy to slow the progression of MS.